Literature DB >> 8991791

Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference.

J P Stables1, M Bialer, S I Johannessen, H J Kupferberg, R H Levy, P Loiseau, E Perucca.   

Abstract

The Second Eilat Conference on New Antiepileptic Drugs was held at the King Solomon's Palace Hotel from October 31 to November 3, 1994. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss new trial designs, drug approval, early use of new antiepileptic drugs, and new drugs in development. Over the last six years, several novel antiepileptic drugs have been introduced worldwide, and new information on their safety and efficacy has become available. These include felbamate, gabapentin, lamotrigine, oxcarbazepine, and vigabatrin. Drugs in development include those at an advanced stage, such as topiramate and tiagabine, as well as those just entering clinical trials, such as remacemide and levetiracetam. The following is a summary of the presentations for drugs in development and newly marketed drugs. The meeting concluded with a presentation, 'Still Searching for the Magic Bullet'.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8991791     DOI: 10.1016/0920-1211(95)00054-2

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  6 in total

Review 1.  Management of focal-onset seizures: an update on drug treatment.

Authors:  Svein I Johannessen; Elinor Ben-Menachem
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Choice and use of newer anticonvulsant drugs in older patients.

Authors:  L J Willmore
Journal:  Drugs Aging       Date:  2000-12       Impact factor: 3.923

Review 3.  Pharmacokinetic interactions of the new antiepileptic drugs.

Authors:  B Rambeck; U Specht; P Wolf
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 4.  Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice.

Authors:  S Natsch; Y A Hekster; A Keyser; C L Deckers; H Meinardi; W O Renier
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

Review 5.  The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.

Authors:  E Perucca; M Bialer
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

6.  Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers.

Authors:  Margherita Strolin Benedetti; Rhys Whomsley; Jean-Marie Nicolas; Colin Young; Eugène Baltes
Journal:  Eur J Clin Pharmacol       Date:  2003-10-07       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.